What is he best known for?
The fields of study he is best known for:
- Gene
- Internal medicine
- Cancer
Internal medicine, Pathology, Immunology, Kidney and Antibody are his primary areas of study.
The concepts of his Internal medicine study are interwoven with issues in Gastroenterology and Endocrinology.
His Pathology research is multidisciplinary, incorporating elements of Monoclonal Immunoglobulin Deposition Disease, Monoclonal, Nephropathy and Glomerulopathy.
He has researched Immunology in several fields, including Glomerulonephritis, Glomerular basement membrane and Amyloidosis.
His Kidney research includes themes of Brush border, Kidney cancer, Kidney disease, Cancer cell and Extracellular matrix.
His research in Antibody intersects with topics in Heymann Nephritis, Yolk sac and Biochemistry.
His most cited work include:
- Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis (947 citations)
- High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. (378 citations)
- Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. (361 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Pathology, Immunology, Membranous nephropathy and Antibody.
His Internal medicine research integrates issues from Gastroenterology and Endocrinology.
The study incorporates disciplines such as Nephropathy and Glomerulopathy in addition to Pathology.
His biological study spans a wide range of topics, including Glomerulonephritis and Glomerular basement membrane.
The Membranous nephropathy study combines topics in areas such as Complement system, Nephrotic syndrome, Biopsy, Podocyte and Rituximab.
His work deals with themes such as Heymann Nephritis and Neprilysin, which intersect with Antibody.
He most often published in these fields:
- Internal medicine (46.80%)
- Pathology (31.07%)
- Immunology (29.90%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (46.80%)
- Membranous nephropathy (31.46%)
- Gastroenterology (14.37%)
In recent papers he was focusing on the following fields of study:
Pierre Ronco spends much of his time researching Internal medicine, Membranous nephropathy, Gastroenterology, Pathology and Nephrotic syndrome.
His work on Nephrology, Renal function, Kidney disease and Retrospective cohort study as part of general Internal medicine study is frequently linked to In patient, bridging the gap between disciplines.
His Membranous nephropathy study integrates concerns from other disciplines, such as Immunohistochemistry and Autoantibody, Autoimmune disease, Antibody, Rituximab.
His study on Antibody is covered under Immunology.
His research integrates issues of Glomerulonephritis and Podocyte in his study of Pathology.
His Nephrotic syndrome research is multidisciplinary, relying on both Genetics, Gene and Disease.
Between 2017 and 2021, his most popular works were:
- Exostosin 1/Exostosin 2-Associated Membranous Nephropathy. (55 citations)
- Clearance of carbapenem-resistant Enterobacteriaceae vs vancomycin-resistant enterococci carriage after faecal microbiota transplant: a prospective comparative study. (34 citations)
- High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy (30 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Internal medicine
- Cancer
His scientific interests lie mostly in Membranous nephropathy, Internal medicine, Cohort, Gastroenterology and Complement system.
His Membranous nephropathy research includes elements of Autoimmune disease, Human leukocyte antigen, Antigen and Pathology.
His studies deal with areas such as Receptor, Glomerulonephritis and Factor H as well as Pathology.
Pierre Ronco combines subjects such as Carriage, Antibiotics and Colonization with his study of Internal medicine.
Pierre Ronco focuses mostly in the field of Gastroenterology, narrowing it down to topics relating to Rituximab and, in certain cases, Cyclophosphamide.
Pierre Ronco has begun a study into Complement system, looking into Immunology and Antibody.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
